Clinical trial
Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas
NCT00062504 · Teva Branded Pharmaceutical Products R&D, Inc., Industry · Terminated
Key facts
| NCT number | NCT00062504 |
|---|---|
| Title | Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas |
| Official title | A Phase II Trial of Talampanel in Patients With Recurrent High-Grade Gliomas. |
| Lead sponsor | Teva Branded Pharmaceutical Products R&D, Inc., Industry |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Mixed Oligoastrocytoma |
| Intervention type | Drug |
| Interventions | Talampanel |
| Enrollment | 30 |
| Start date | Jul 1, 2003 |
| Primary completion | Jan 1, 2006 |
| Completion | Apr 1, 2006 |
| First posted | Jun 12, 2003 |
| Last update posted | May 23, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: